Study of BHV-1400 in IgA Nephropathy

This trial tests a new drug called BHV-1400 in people with IgA nephropathy — a kidney disease where a protein called IgA builds up in the kidneys and causes inflammation and progressive kidney damage. BHV-1400 is designed to reduce the IgA deposits and slow down kidney damage. **You may be eligible if...** - You have been diagnosed with IgA nephropathy confirmed by kidney biopsy - You are experiencing signs of progressive kidney damage (such as protein in the urine) - You meet the health criteria to take part in the study **You may NOT be eligible if...** - Your IgA nephropathy is secondary (caused by another condition like liver disease or inflammatory bowel disease) - Your kidney disease is caused by something other than IgA nephropathy - You have severely impaired kidney function or are on dialysis Talk to your doctor to see if this trial is right for you.